Accelerating Science Feature
Understanding PFAS exposure, toxicity, and biomonitoring
As PFAS (per- and polyfluoroalkyl substances) contamination becomes increasingly widespread, understanding how these substances move through the environment and accumulate in the human body is critical for assessing risk and protecting public health.
As part of our wider Accelerating Science in PFAS feature, this topic explores current approaches to PFAS exposure assessment, toxicity evaluation, and biomonitoring, highlighting how advances in analytical science are enabling more sensitive, reliable measurement of PFAS in biological and environmental samples. Through expert insight and real-world examples, we examine how robust biomonitoring data are informing risk assessment, regulatory decision-making, and long-term strategies to reduce PFAS-related health impacts.
View the main feature pageExplore latest content in this topic
Overcoming the sensitivity vs. robustness trade-off in mass spectrometry
Discover how the Xevo™ TQ Absolute XR Mass Spectrometer, already used by pharmaceutical companies for bio analysis, can analyze the dirtiest of matrices, to detect the lowest level of contaminants, including PFAS.
Watch video
Exploring biomonitoring of short-chain PFAS
Uncover a biomonitoring approach for the analysis of ultrashort-chain PFAS in human plasma and serum samples to improve understanding of their potential adverse effects on human health.
Download resource
Determination of PFAS in pharmaceutical water used for development of injectable drugs using a high-speed triple quadrupole
This study demonstrates the risk of potential leaching from IV bag-type packaging and how LC-MS/MS can be used to detect PFAS in pharmaceutical-grade water.
Download resourceAccelerating Science Forum
Advancing PFAS biomonitoring: What we measure and why it matters
Live May 27, 2026
Register nowThis Accelerating Science Forum will bring together world-leading PFAS experts to discuss:
- How advances in LC‑MS/MS, HRMS, and multi‑omics are redefining PFAS biomonitoring
- Which PFAS compounds, metabolites, and exposure biomarkers should be prioritized for meaningful assessment
- How measurement challenges (e.g. ultra‑trace detection, matrix effects, isomer resolution) directly influence toxicological models and global risk assessment
- Emerging analytical strategies supporting evidence‑based legislation and population‑level health protection
Become a member
Never miss an update
The PFAS landscape moves fast. Don't get left behind.
Join us to get the latest PFAS news, expert insights, and regulatory updates delivered straight to your inbox, along with regular newsletters covering key developments in environmental and analytical science.
Register free today